Search Results - "Chaft, J.E."

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) by Cottrell, T.R., Thompson, E.D., Forde, P.M., Stein, J.E., Duffield, A.S., Anagnostou, V., Rekhtman, N., Anders, R.A., Cuda, J.D., Illei, P.B., Gabrielson, E., Askin, F.B., Niknafs, N., Smith, K.N., Velez, M.J., Sauter, J.L., Isbell, J.M., Jones, D.R., Battafarano, R.J., Yang, S.C., Danilova, L., Wolchok, J.D., Topalian, S.L., Velculescu, V.E., Pardoll, D.M., Brahmer, J.R., Hellmann, M.D., Chaft, J.E., Cimino-Mathews, A., Taube, J.M.

“…Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with…”
Get full text

NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer by Forde, P.M., Smith, K.N., Chaft, J.E., Hellmann, M., Merghoub, T., Wolchok, J.D., Yang, S.C., Battafarano, R.J., Gabrielson, E., Georgiades, C.S., Verde, F., Rosner, G.L., Naidoo, J., Cottrell, T.R., Taube, J.M., Anagnostou, V., Velculescu, V.E., Topalian, S.L., Pardoll, D.M., Brahmer, J.R.

Get full text

503 Pneumonitis with anti-PD-1/PD-L1 therapy by Naidoo, J, Cunningham, J, Woo, K.M, Hellmann, M.D, Postow, M.A, Drilon, A.E, Chaft, J.E, Lesokhin, A.M, Segal, N.H, Callahan, M.K, Rudin, C.M, Iyriboz, T, Wolchok, J.D

Get full text

Stage III Non-Small Cell Lung Cancer Treated Without Concurrent Chemotherapy: What Is the Optimal Radiation Dose? by Rimner, A, Din, S, Shaikh, F, Foster, A, Tyagi, N, Abi Aad, S, Paik, P, Yorke, E.D, Chaft, J.E, Gelblum, D.Y, Rosenzweig, K.E, Wu, A.J

Get full text

Prognostic Factors for Postresection Recurrent NSCLC Treated With Definitive Radiation Therapy by Garay, E, Rimner, A, Foster, A, Hsu, M, Zhang, Z, Huang, J, Chaft, J.E, Rosenzweig, K.E, Wu, A.J

Get full text

Stage III Non-Small Cell Lung Cancer Treated Without Concurrent Chemotherapy: What Is the Optimal Radiation Dose? by Rimner, A, Din, S, Shaikh, F, Foster, A, Tyagi, N, Abi Aad, S, Paik, P, Yorke, E.D, Chaft, J.E, Gelblum, D.Y, Rosenzweig, K.E, Wu, A.J

Get full text

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer by Derosa, L., Hellmann, M.D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A.J., Arbour, K.C., Chaft, J.E., Rouche, J.A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., Routy, B.

“…The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer…”
Get full text

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer by Osorio, J.C., Ni, A., Chaft, J.E., Pollina, R., Kasler, M.K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J.D., Merghoub, T., Rudin, C.M., Fish, S., Hellmann, M.D.

“…Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is…”
Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

Chemotherapy remains an essential element of personalized care for persons with lung cancers by Hellmann, M.D., Li, B.T., Chaft, J.E., Kris, M.G.

“…Molecularly targeted and immunotherapies have improved the care of patients with lung cancers. These successes have rallied calls to replace or avoid…”
Get full text

Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors by Shaverdian, N., Beattie, J., Thor, M., Offin, M., Shepherd, A.F., Gelblum, D.Y., Wu, A.J., Simone, C.B., Hellmann, M.D., Chaft, J.E., Rimner, A., Gomez, D.R.

“…Immune checkpoint inhibitors (ICIs) and thoracic radiotherapy are increasingly used to treat advanced cancers. Despite data indicating exaggerated radiation…”
Get full text

192P Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis by Moore, Z.R., Rimner, A., Lobaugh, S., Geyer, A., Gelblum, D.Y., Shepherd, A.F., Shaverdian, N., Wu, A.J., Chaft, J.E., Zauderer, M.G., Rudin, C.M., Vander Els, N., Chawla, M., Jones, D.R., Sopka, D.M., Mak, R., Liao, Z., Gomez, D.R., Zhang, Z., Paik, P.

Get full text

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC by Kris, M.G., Grindheim, J.M., Chaft, J.E., Lee, J.M., Johnson, B.E., Rusch, V.W., Bunn, P.A., Pass, H., Schum, E., Carlisle, J., Weyant, M., Nicholas, A., Johnson, A., Shames, D., Wistuba, I.I., Carbone, D.P., Schulze, K., Kwiatkowski, D.J.

Get full text

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer by Forde, Patrick M., Chaft, Jamie E., Smith, Kellie N., Anagnostou, Valsamo, Cottrell, Tricia R., Hellmann, Matthew D., Zahurak, Marianna, Yang, Stephen C., Jones, David R., Broderick, Stephen, Battafarano, Richard J., Velez, Moises J., Rekhtman, Natasha, Olah, Zachary, Naidoo, Jarushka, Marrone, Kristen A., Verde, Franco, Guo, Haidan, Zhang, Jiajia, Caushi, Justina X., Chan, Hok Yee, Sidhom, John-William, Scharpf, Robert B., White, James, Gabrielson, Edward, Wang, Hao, Rosner, Gary L., Rusch, Valerie, Wolchok, Jedd D., Merghoub, Taha, Taube, Janis M., Velculescu, Victor E., Topalian, Suzanne L., Brahmer, Julie R., Pardoll, Drew M.

Get full text

Stage III Non-Small Cell Lung Cancer Treated Without Concurrent Chemotherapy: What Is the Optimal Radiation Dose?: Locally Advanced Non-Small Cell Lung Cancer by Rimner, A., Din, S., Shaikh, F., Foster, A., Tyagi, N., Abi Aad, S., Paik, P., Yorke, E.D., Chaft, J.E., Gelblum, D.Y., Rosenzweig, K.E., Wu, A.J.

Get full text